SCHEMBL14955882

SCHEMBL14955882

CCC(CC)COc1ccccc1Cn1nc(CC(C)C(=O)O)cc1C

nearest known ligand 0.44

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 18/20 0.44
CYP1A2 P05177 2/20 0.39
SLC16A3 O15427 2/20 0.39
SLC16A1 P53985 2/20 0.39
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14963578 1.00 PTGER1 (0.44) PTGER1CYP1A2SLC16A3SLC16A1CYP2C9
SCHEMBL14963576 0.87 PTGER1 (0.50) PTGER1CYP1A2
SCHEMBL14955371 0.87 PTGER1 (0.50) PTGER1CYP1A2
SCHEMBL14963575 0.87 PTGER1 (0.57) PTGER1
SCHEMBL14955583 0.87 PTGER1 (0.57) PTGER1
SCHEMBL14955939 0.75 PTGER1 (0.41) PTGER1CYP1A2
SCHEMBL14955759 0.75 PTGER1 (0.52) PTGER1CYP1A2
SCHEMBL14956205 0.75 PTGER1 (0.43) PTGER1CYP1A2
SCHEMBL14956068 0.74 PTGER1 (0.44) PTGER1CYP1A2
SCHEMBL254655 0.73 PTGER1 (0.52) PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2945932-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-11-21 EP claimed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US claimed
EP-2945932-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-11-21 EP disclosed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US disclosed
EP-2945932-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2015-11-25 EP disclosed
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2015-03-19 US disclosed
US-8859606-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2014-10-14 US disclosed
WO-2014113814-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-07-24 WO disclosed
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP1A2 482/4885SLC16A3 3046/4885
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP1A2 482/4885SLC16A3 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.